ISCARE a.s.

Futó vizsgálatok

• Toboroz

  A clinical trial to assess the efficacy and safety of ontunisertib compared to placebo in patients with fibrostenosing Crohn’s disease

  2026-525197-19-00· 2. fázis· Forrás

• Toboroz

  A study of LY4268989 in participants with Moderately to Severely Active Ulcerative Colitis (EMERALD-3)

  2025-524404-29-00· 2. fázis· Forrás

• Toboroz

  A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07577856· 3. fázis· Forrás

• Toboroz

  A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

  NCT07577843· 3. fázis· Forrás

• Toboroz

  A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008)

  2024-518296-56-00· 3. fázis· Forrás

• Toboroz

  A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

  NCT06819891· 3. fázis· Forrás

• Toboroz

  A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease

  NCT06227910· 3. fázis· Forrás

• Fut, nem toboroz

  A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT06588855· 3. fázis· Forrás

• Toboroz

  A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis

  NCT06636656· 2. fázis· Forrás

• Toboroz

  Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease

  NCT06456593· 2. fázis· Forrás

• Toboroz

  Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

  NCT06548542· 2. fázis· Forrás

• Toboroz

  A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

  NCT06430801· 3. fázis· Forrás

• Fut, nem toboroz

  Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients

  NCT06408935· 3. fázis· Forrás

• Fut, nem toboroz

  A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease

  NCT05242471· 2. fázis· Forrás

• Fut, nem toboroz

  Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)

  NCT04524611· 3. fázis· Forrás

• Fut, nem toboroz

  A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT04033445· 2/3. fázis· Forrás

• Fut, nem toboroz

  A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

  NCT03466411· 2/3. fázis· Forrás

• Fut, nem toboroz

  A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease

  NCT03105102· 3. fázis· Forrás

• Fut, nem toboroz

  A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)

  NCT03006068· 3. fázis· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Crohn-betegség7 toboroz
• Colitis ulcerosa3 toboroz

Kutatók

Ide még nem kötődik kutató.

Lezárt vizsgálatok

• Lezárult

  A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants with Moderate to Severe Ulcerative Colitis

  2023-506655-19-00· 2. fázis· Forrás

• Lezárult

  A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT06049017· 2. fázis· Forrás

• Fut, nem toboroz

  Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis

  NCT05588843· 2. fázis· Forrás

• Lezárult

  A Long-term Safety Study of a Second Treatment with Darvadstrocel for Treating Complex Perianal Fistulas in Adults with Crohn's Disease

  NCT04118088· 4. fázis· Forrás

• Lezárult

  Multicenter Extension Study of Oral Ozanimod in patients with Moderately to Severely Active Crohn's Disease

  2024-511553-22-00· 3. fázis· Forrás